{"id":"https://openalex.org/W3039922003","doi":null,"title":"Pharmacokinetics and Ocular Tolerability of Suprachoroidal CLS-AX (axitinib injectable suspension) in rabbits","display_name":"Pharmacokinetics and Ocular Tolerability of Suprachoroidal CLS-AX (axitinib injectable suspension) in rabbits","alternate_titles":[],"publication_year":2020,"publication_date":"2020-06-10","ids":{"openalex":"https://openalex.org/W3039922003","mag":"3039922003"},"language":"en","primary_location":{"id":"mag:3039922003","doi":null,"is_oa":true,"landing_page_url":"https://iovs.arvojournals.org/article.aspx?articleid=2768760","pdf_url":null,"source":{"id":"https://openalex.org/S76304953","display_name":"Investigative Ophthalmology & Visual Science","issn_l":"0146-0404","issn":["0146-0404","1552-5783"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310321950","host_organization_name":"Cadmus Press","host_organization_lineage":["https://openalex.org/P4310321950"],"host_organization_lineage_names":["Cadmus Press"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Investigative Ophthalmology & Visual Science","raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W3039922003"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://iovs.arvojournals.org/article.aspx?articleid=2768760","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5027905724","display_name":"Leroy W. Muya","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114463","display_name":"Clearside Biomedical (United States)","ror":"https://ror.org/0250cw529","country_code":"US","type":"company","lineage":["https://openalex.org/I4210114463"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Leroy Muya","raw_affiliation_strings":["Clearside Biomedical Inc. , Alpharetta, Georgia, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clearside Biomedical Inc. , Alpharetta, Georgia, United States","institution_ids":["https://openalex.org/I4210114463"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087138805","display_name":"Viral S. Kansara","orcid":"https://orcid.org/0000-0003-0910-8686","observed_orcids":["https://orcid.org/0000-0003-0910-8686"]},"institutions":[{"id":"https://openalex.org/I4210114463","display_name":"Clearside Biomedical (United States)","ror":"https://ror.org/0250cw529","country_code":"US","type":"company","lineage":["https://openalex.org/I4210114463"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Viral Kansara","raw_affiliation_strings":["Clearside Biomedical Inc. , Alpharetta, Georgia, United States"],"raw_orcid":"https://orcid.org/0000-0003-0910-8686","affiliations":[{"raw_affiliation_string":"Clearside Biomedical Inc. , Alpharetta, Georgia, United States","institution_ids":["https://openalex.org/I4210114463"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5036246396","display_name":"Thomas A. Ciulla","orcid":"https://orcid.org/0000-0001-5557-6777","observed_orcids":["https://orcid.org/0000-0001-5557-6777"]},"institutions":[{"id":"https://openalex.org/I4210114463","display_name":"Clearside Biomedical (United States)","ror":"https://ror.org/0250cw529","country_code":"US","type":"company","lineage":["https://openalex.org/I4210114463"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Thomas A. Ciulla","raw_affiliation_strings":["Clearside Biomedical Inc. , Alpharetta, Georgia, United States"],"raw_orcid":"https://orcid.org/0000-0001-5557-6777","affiliations":[{"raw_affiliation_string":"Clearside Biomedical Inc. , Alpharetta, Georgia, United States","institution_ids":["https://openalex.org/I4210114463"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210114463"],"apc_list":{"value":1850,"currency":"USD","value_usd":1850},"apc_paid":{"value":1850,"currency":"USD","value_usd":1850},"fwci":1.6913,"has_fulltext":false,"cited_by_count":14,"citation_normalized_percentile":{"value":0.81448639,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":97},"biblio":{"volume":"61","issue":"7","first_page":"4925","last_page":"4925"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.18199999630451202,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.18199999630451202,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10250","display_name":"Glaucoma and retinal disorders","score":0.17579999566078186,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10920","display_name":"Advanced Drug Delivery Systems","score":0.1371999979019165,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/axitinib","display_name":"axitinib","score":0.9739999771118164},{"id":"https://openalex.org/keywords/suprachoroidal-injection","display_name":"suprachoroidal injection","score":0.8450000286102295},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.890999972820282},{"id":"https://openalex.org/keywords/ocular-tolerability","display_name":"ocular tolerance","score":0.9750000238418579},{"id":"https://openalex.org/keywords/choroidal-neovascularization","display_name":"choroidal neovascularization","score":0.7289999723434448},{"id":"https://openalex.org/keywords/anti-vegf-therapy","display_name":"anti-VEGF therapy","score":0.8349999785423279},{"id":"https://openalex.org/keywords/rabbit-model","display_name":"rabbit model","score":0.43700000643730164}],"concepts":[{"id":"https://openalex.org/C190729725","wikidata":"https://www.wikidata.org/wiki/Q5012817","display_name":"CLs upper limits","level":2,"score":0.8130111694335938},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7003787159919739},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6904435157775879},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6390988230705261},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4930884540081024},{"id":"https://openalex.org/C2776539811","wikidata":"https://www.wikidata.org/wiki/Q4830631","display_name":"Axitinib","level":4,"score":0.48758643865585327},{"id":"https://openalex.org/C118487528","wikidata":"https://www.wikidata.org/wiki/Q161437","display_name":"Ophthalmology","level":1,"score":0.4453858435153961},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.13758215308189392},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.06993979215621948},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.04157763719558716},{"id":"https://openalex.org/C2779490328","wikidata":"https://www.wikidata.org/wiki/Q417542","display_name":"Sunitinib","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:3039922003","doi":null,"is_oa":true,"landing_page_url":"https://iovs.arvojournals.org/article.aspx?articleid=2768760","pdf_url":null,"source":{"id":"https://openalex.org/S76304953","display_name":"Investigative Ophthalmology & Visual Science","issn_l":"0146-0404","issn":["0146-0404","1552-5783"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310321950","host_organization_name":"Cadmus Press","host_organization_lineage":["https://openalex.org/P4310321950"],"host_organization_lineage_names":["Cadmus Press"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Investigative Ophthalmology & Visual Science","raw_type":null}],"best_oa_location":{"id":"mag:3039922003","doi":null,"is_oa":true,"landing_page_url":"https://iovs.arvojournals.org/article.aspx?articleid=2768760","pdf_url":null,"source":{"id":"https://openalex.org/S76304953","display_name":"Investigative Ophthalmology & Visual Science","issn_l":"0146-0404","issn":["0146-0404","1552-5783"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310321950","host_organization_name":"Cadmus Press","host_organization_lineage":["https://openalex.org/P4310321950"],"host_organization_lineage_names":["Cadmus Press"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Investigative Ophthalmology & Visual Science","raw_type":null},"sustainable_development_goals":[{"score":0.9391000270843506,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2582874353","https://openalex.org/W2584979038","https://openalex.org/W3172979570","https://openalex.org/W805230980","https://openalex.org/W3086087279","https://openalex.org/W2738712990","https://openalex.org/W2992315846","https://openalex.org/W4223473283","https://openalex.org/W760538984","https://openalex.org/W949623730"],"abstract_inverted_index":null,"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W3039922003","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2020-07-10T00:00:00"}
